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ABSTRACT  
Publications that compare randomized controlled trial and cohort study results on the effects of 
postmenopausal estrogen plus progestin therapy are reviewed.  The two types of studies agree in 
identifying an early elevation in coronary heart disease risk, and a later developing elevation in 
breast cancer risk.  Effects among women who begin hormone therapy within a few years 
following the menopause may be comparatively more favorable for coronary heart disease and 
less favorable for breast cancer.  These analyses illustrate the potential of modern data analysis 
methods to enhance the reliability and interpretation of epidemiologic data. 
 
1. INTRODUCTION 
There is a pressing need to find ways to assess, and enhance as necessary, the reliability of 
findings from observational studies (OSs).  Available methods for controlling confounding, 
measurement error and other biases can be expected to provide adjustments in the desired 
direction, but objective means of assessing bias avoidance are generally lacking.  Randomized 
controlled trials (CTs) include an objective assignment of a study treatment or intervention, and 
avoid confounding by pre-randomization factors.  However, CTs tend to be expensive and 
typically cannot be conducted in a manner that powerfully addresses subset hypotheses, or 
treatment effects over a lengthy exposure period.  Hence, the population science research agenda 
must rely heavily on observational studies for the development and initial testing of disease 
prevention hypotheses, with CTs typically conducted only for well-established hypotheses 
having strong public health potential.   
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Settings in which both CTs and OSs are available provide a particularly opportunity to examine 
consistency of results from the two types of studies, and to identify improvements in study 
design, conduct, or analysis that may help to explain any discrepancy in results.  Such data exist 
for postmenopausal hormone therapy (HT) in relation to several important clinical outcomes, and 
few topics having generated more interest and controversy in recent years, in part because CT 
and OS findings appeared to be strongly discrepant. 
 
2. BENEFITS AND RISKS OF POSTMENOPAUSAL HORMONE THERAPY 
A substantial body of cohort and case-control studies suggested that postmenopausal hormone 
therapy would reduce coronary heart disease (CHD) risk perhaps by about 40-50%, with little 
indication for a difference in effects between estrogen-alone or estrogen plus progestin.1, 2  A 
later developing extensive observational literature also suggested elevations in breast cancer risk, 
by about 30% for estrogen, and 50-100% for estrogen plus progestin.3, 4  Reports that were 
available by the early 1990s informed the design of the Women’s Health Initiative (WHI) CTs of 
0.625 mg daily conjugated equine estrogen (CEE) among 10,739 women who were post-
hysterectomy, and of this same estrogen regimen plus 2.5 mg/day medroxyprogesterone acetate 
(CEE/MPA) among 16,608 women with uterus.  CHD was the designated primary outcome with 
breast cancer as the primary ‘safety’ outcome in both trials.  A recruitment age range of 50-79 
was specified to examine whether health benefits and risk would apply broadly to 
postmenopausal women.  At the time these trials were initiated the CEE and CEE/MPA regimens 
under study were used by about 8 and 6 million women respectively in the United States. 
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With this background it came as quite a surprise when the CEE/MPA trial was stopped 
prematurely in 2002 when it was judged that health risks exceeded benefits over its 5.6-year 
average follow-up period.  The health risks included elevations in breast cancer, stroke, venous 
thromboembolism (VT), and CHD, which were only partially offset by reductions in fracture and 
colorectal cancer.5  Though breast cancer was a trigger for early stopping, the hazard ratio (HR) 
estimate was a moderate 1.24 with 95% confidence interval (CI) from 1.01 to 1.54.6  More 
surprising was the HR of 1.24 (95% CI from 1.00 to 1.54) for CHD, with an HR of 1.81 (95% CI 
from 1.09 to 3.01) during the first year of CEE/MPA use.7 
 
WHI investigators undertook joint analyses of data from this CT with that from a corresponding 
subset of the WHI observational Study (OS), which was comprised of women recruited from the 
same population as the CT, with much commonality in eligibility criteria, baseline data 
collection, and outcome ascertainment.  HRs from the OS alone were considerably lower than for 
the RCT and similar to those from other cohort studies following confounding control, for each 
of CHD, stroke, and VT.8  However, CHD HRs were found to agree closely following control for 
time from hormone therapy initiation (duration of use among adherent women).  The same 
analytic techniques, however, did not appear to fully explain the lower stroke HR from the OS 
compared to the CT.   
 
The WHI CEE trial also ended early in 2004, based on a stroke elevation of similar magnitude to 
that for CEE/MPA (HR of about 1.3), and a limited power to establish a CHD effect prior to the 
trial’s planned termination.9  The HR (95% CI) for CHD was 0.95 (0.79, 1.15), while that for 
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breast cancer was a rather surprising 0.80 (0.62, 1.04) over the trial’s follow-up period that 
averaged 7.1 years.10, 11 
 
Comparative analysis of WHI CT and OS analyses for CHD, stroke, and VT yielded almost 
identical results for CEE as for CEE/MPA.  HRs from the two sources agreed closely for CHD 
and VT, and not so closely for stroke, after confounding control upon allowing the HR to depend 
on time from CEE initiation.12  In fact, the ratio of CT to OS HRs was about 0.9 for CHD and 
VT, and about 0.7 for stroke for both CEE and CEE/MPA, presumably suggesting some residual 
bias for stroke. 
 
Recently analyses of this type have also been presented for breast cancer.13, 14  HRs from the OS 
were somewhat higher than those from the RCT for both CEE/MPA and CEE even after control 
confounding and accommodating time since HT initiation.  These HRs, however, were found to 
be higher among women who first initiated HT within a few years following the menopause 
compared to women having larger gap times, and HRs agreed closely between the two data 
sources after allowing effect modification by this gap time variable.  Among women having gap 
times of less than 5 years the breast cancer HR increased to about 2.0 following two or more 
years of CEE/MPA, while that for CEE was about 1.0. 
 
The types of modeling and comparative analyses just described achieve some robustness by 
virtue of similar findings between CEE/MPA and CEE, but it is also of great interest to compare 
WHI CT results with results from other observational studies, including the Nurses Health Study 
5 
 
(NHS) which played an important role in the generation and initial testing of hypotheses related 
to HT effects. 
 
3. CEE/MPA AND CHD IN THE NURSES HEALTH STUDY 
In this issue Hernán et al15 provide a reanalysis of the association between CEE/MPA and CHD 
in the NHS.  These authors are to be congratulated on a careful matching of the NHS subset used 
(34,575 women) to the set of women enrolled in the WHI CEE/MPA trial, and for a series of 
analyses that elucidate the impact of various analytic definitions and estimation procedures on 
the resulting HRs.  Also, the participating NHS coauthors are to be congratulated for allowing 
their data to be subjected to the novel analytic approaches employed.  Compared to the WHI OS, 
the NHS has the distinct advantage that much of the CEE/MPA use was initiated following 
cohort enrollment, potentially allowing precise assessment of benefits and risks during the early 
months following HT initiation.  Previous analyses of NHS data evidently relied on a biennial 
snapshot of current HT user status.  This was evidently an important analytic limitation for 
estimation of an early HR increase that substantially dissipated within a year or two following 
CEE/MPA initiation.  For example, women who initiate CEE/MPA would be classified based on 
this snapshot as non-users until their biennial data collection time, and permanently as non-users 
if they stop usage prior to such collection.16  In the present analysis the authors recover 
‘estimates’ of the date of HT initiation to the extent possible through a fuller use of available 
data, presumably substantially mitigating this source of bias.  They also attempt to emulate a CT 
by defining a multivariate response for each woman by classifying her as an initiator or non-
initiator in each two-year follow-up interval and estimating an initiator vs. non-initiator HR from 
the follow-up of each such ‘stratum’ with appropriate provision for dependencies that arise from 
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individual woman contributing to several (up to 8) HR estimates.  There was little evidence that 
such HR estimates differed among strata, and the resulting common HR estimates agreed closely 
with corresponding estimates from the WHI CT with HR estimate (95% CI) of 1.42 (0.92, 2.20) 
for the first two years of use, and 0.96 (0.78, 1.18) over the entire follow-up period.  Note that 
this type of CT emulation methodology was not needed for analysis of the WHI OS, since there 
were few HT initiators following cohort enrollment. 
 
Hernán and colleagues go on to describe a possible interaction (p=0.08) of HR with years from 
menopause to CEE/MPA initiation.  Among women having fewer than 10 years from menopause 
to HT initiation the HR (95% CI) was 1.28 (0.62, 0.84) in the first two years of follow-up, and 
0.81 (0.56, 1.17) thereafter.  Such an interaction was not evident in the WHI trial, and would 
benefit from study in other settings. 
 
4. INTENTION-TO-TREAT AND ADHERENCE ADJUSTMENT 
Hernán and colleagues include some rather harsh criticisms of intention-to-treat (ITT) analyses, 
indicating that ITT estimates ‘may be unsatisfactory when studying efficacy, and inappropriate 
when studying the safety, of an active treatment compared to no treatment’.  It seems worth 
reiterating that of the various analyses discussed here only for the CT ITT comparisons can we 
be sure that the treated and untreated groups are fully comparable at enrollment.  Hence, if the 
clinical outcomes are equally ascertained between the active and placebo groups, a causal 
interpretation for the treatment and its sequelae is justified for any differences that emerge.  By 
comparison, what Hernán and colleagues refer to as an ITT analysis of the NHS data attempts to 
argue toward a causal interpretation by virtue of careful confounding control, and 
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accommodation of time of HT initiation, and time since HT initiation, and there is limited ability 
in the absence of corresponding CT data, to assess the success of these efforts. 
 
However, there are important questions to answer beyond ITT comparisons, including estimating 
the magnitude of treatment effects among study subjects who adhere to the treatment regimen.  
Even the CT setting does not allow a HR function for adherent women to be estimated without 
making additional assumptions.  Women who adhere to treatment or non-treatment status may 
have many biobehavioral differences from those who do not, and these characteristics may differ 
between treated and non-treated groups.  A CT that is able to maintain an effective blinding of 
active versus placebo status may yield fairly comparable groups of adherent women.5  
Nevertheless, WHI investigators describe comparisons between women adherent to active and 
placebo pill taking as sensitivity analysis to alert the reader to possible non-comparability 
between these groups. 
 
Some adherence-adjusted analyses in WHI have simply censored the follow-up of women soon 
after they become non-adherent.  Including inverse censoring probability weighting (ICPW) as in 
Hernán et al, could presumably enhance these comparisons, by attempting to restore a contrast 
that is theoretically applicable to the entire randomized group.  While this ICPW method is a 
useful step forward, it is worth noting that the justification for the adherence-adjusted HRs that 
emerge depends directly on the ability to adequately model the non-adherence process.  Doing so 
is analogous to modeling to control confounding.  One presumably needs detailed knowledge of, 
and accurate measurement and modeling of, the factors that may determine adherence to each 
treatment group in the study population.  It would seem that the knowledge base for this type of 
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activity is still limited, arguing for a suitably circumspect interpretation of resulting HR 
estimates.  HRs among adherent women tend to be more extreme in their departure from the null 
than do ITT analyses for both the cardiovascular disease and breast cancer outcomes for each of 
the data sources considered here. 
 
5. CONCLUDING COMMENT 
Excellent progress has been made in recent decades on the development of data analytic methods 
for trials and observational studies emanating, in part, from the Cox17 hazard ratio regression 
model and its multivariate extensions.  The reanalysis of Hernán et al strongly suggest that the 
use of these methods can strengthen the analysis and interpretation of observational studies.  
Still, it seems evident that CTs are needed when preventive interventions are widely used, or 
when the public health implications are sufficiently large.  In the special case of postmenopausal 
HT the state of knowledge of health benefits and risks is quite different following the WHI trials 
than had been assumed in advance, and it is interesting to question whether an early elevation in 
CHD risk, or a more sustained elevation in stroke and dementia risk,18-20 would have been 
identified in the absence of CT data? 
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